Purple Biotech Reports Positive Phase 2 Pancreatic Cancer Study Results
Ticker: PPBT · Form: 6-K · Filed: Dec 2, 2024 · CIK: 1614744
Sentiment: bullish
Topics: clinical-trial-results, oncology, drug-development
TL;DR
Purple Biotech's CM24 shows promise in Phase 2 pancreatic cancer trial, hitting key survival endpoint.
AI Summary
On December 2, 2024, Purple Biotech Ltd. announced positive final results from a Phase 2 study of its drug CM24 in patients with second-line pancreatic cancer. The study met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival (PFS) for patients treated with CM24 in combination with chemotherapy compared to chemotherapy alone.
Why It Matters
Positive Phase 2 results for CM24 in pancreatic cancer could advance the drug towards later-stage trials and potential market approval, offering a new treatment option for a difficult-to-treat disease.
Risk Assessment
Risk Level: medium — Phase 2 results are promising but require further validation in larger Phase 3 trials, and regulatory approval is not guaranteed.
Key Numbers
- Phase 2 — Study Phase (Indicates the stage of clinical development for CM24)
Key Players & Entities
- Purple Biotech Ltd. (company) — Filer of the report and developer of CM24
- CM24 (drug) — Investigational drug studied in the Phase 2 trial
- Pancreatic Cancer (disease) — Indication for which CM24 was studied
- December 2, 2024 (date) — Date of the press release and filing
FAQ
What was the primary endpoint of the Phase 2 study for CM24?
The press release states the study met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival (PFS).
What is the indication being studied for CM24?
CM24 is being studied in second-line pancreatic cancer.
When did Purple Biotech Ltd. issue the press release regarding these results?
The press release was issued on December 2, 2024.
What is the filing form type?
The filing form type is a 6-K.
What was the former name of Purple Biotech Ltd.?
The company was formerly known as Kitov Pharma Ltd. and Kitov Pharmaceuticals Holdings Ltd.
Filing Stats: 572 words · 2 min read · ~2 pages · Grade level 20 · Accepted 2024-12-02 07:03:25
Filing Documents
- ea0223199-6k_purple.htm (6-K) — 14KB
- ea022319901ex99-1_purple.htm (EX-99.1) — 34KB
- 0001213900-24-104213.txt ( ) — 49KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. December 2, 2024 PURPLE BIOTECH LTD. By: /s/ Gil Efron Gil Efron Chief Executive Officer 2